ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
September 13, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and...
ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
August 15, 2022 17:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
August 02, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
July 27, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
July 08, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on...
PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
June 27, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Announces Debt Amendment and Conversion
June 22, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
June 22, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
June 22, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on...
ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
May 17, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, MA, May 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...